Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Recent evidence indicates that ionizing radiation can enhance immune responses to tumors. Advances in radiation delivery techniques allow hypofractionated delivery of conformal radiotherapy. Hypofractionation or other modifications of standard fractionation may improve radiation’s ability to promote immune responses to tumors. Other novel delivery options may also affect immune responses, including T-cell activation and tumor-antigen presentation changes. However, there is limited understanding of the immunological impact of hypofractionated and unique multifractionated radiotherapy regimens, as these observations are relatively recent. Hence, these differences in radiotherapy fractionation result in distinct immune-modulatory effects. Radiation oncologists and immunologists convened a virtual consensus discussion to identify current deficiencies, challenges, pitfalls and critical gaps when combining radiotherapy with immunotherapy and making recommendations to the field and advise National Cancer Institute on new directions and initiatives that will help further development of these two fields. This commentary aims to raise the awareness of this complexity so that the need to study radiation dose, fractionation, type and volume is understood and valued by the immuno-oncology research community. Divergence of approaches and findings between preclinical studies and clinical trials highlights the need for evaluating the design of future clinical studies with particular emphasis on radiation dose and fractionation, immune biomarkers and selecting appropriate end points for combination radiation/immune modulator trials, recognizing that direct effect on the tumor and potential abscopal effect may well be different. Similarly, preclinical studies should be designed as much as possible to model the intended clinical setting. This article describes a conceptual framework for testing different radiation therapy regimens as separate models of how radiation itself functions as an immunomodulatory ‘drug’ to provide alternatives to the widely adopted ‘one-size-fits-all’ strategy of frequently used 8 Gy×3 regimens immunomodulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“34 35 The degree of cDC1 infiltration in human tumors has also been associated with patient survival.”
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · cited 1×
“19 29–31 In many viral infections, IFN-I is induced by cytosolic DNA that stimulates cGAS to produce cGAMP leading to STING activation.”
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Principles and Practice of Radiation Oncology
Perez, C., & Brady, L. (1999) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199911000-00025 · Cited by 1,871
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834
Self-citationReits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678 · cited 2×
“56 Accordingly, the AKT inhibitor’s efficacy was significantly increased when given 2 hours after MF RT but not when given before or during the MF RT. Similar inducible metabolic changes have been observed following MF and SD RT in several cancer cell lines, especially in fatty acid metabolism.”
Self-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664 · cited 2×
“Given the importance of tumor burden for the response to PD-1 blockade, 39 the best synergy between RT and PD-1 may be seen with doses that more efficiently ‘debulk’ the tumor, at least in some cases.”
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · cited 1×
“102 Next part of the decision tree is the ‘radiation dose’ that can be divided into three dose ranges: low-dose RT (0.1–1 Gy), high-dose RT including ablative and subab-lative (8 Gy and above) and the more standard clinical dose (1.8–2.2 Gy) to define immune modulation effects and how these effects…”
InfluentialAcquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 1×
“38 Whereas both have been shown to have synergistic or additive effects with RT in some preclinical tumor models, the underlying mechanisms are likely to differ.”
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,099
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Self-citationDemaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Self-citationTheelen, W. S. M. E., Peulen, H. M. U., Lalezari, F., van der Noort, V., de Vries, J. F., Aerts, J. G. J. V., Dumoulin, D. W., Bahce, I., Niemeijer, A.-L. N., de Langen, A. J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1478 · Cited by 1,002
The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and Signaling
Cai, X., Chiu, Y.-H., & Chen, Z. J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.040 · Cited by 988
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Formenti, S. C., Rudqvist, N.-P., Golden, E., Cooper, B., Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Friedman, K., Ferrari de Andrade, L., Wucherpfennig, K. W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0232-2 · Cited by 928 · cited 2×
“11 27 28 Thus, it is worth considering if the RT dose that optimally enhances responses may also vary depending on the type of immune checkpoint inhibitor (ie, anti-CTLA-4 vs antiprogrammed cell death protein 1 (anti-PD-1)), as discussed below.”
Self-citationBurnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., Fu, Y.-X., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 878
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
Self-citationHodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0115 · Cited by 688
Self-citationSharabi, A. B., Nirschl, C. J., Kochel, C. M., Nirschl, T. R., Francica, B. J., Velarde, E., Deweese, T. L., & Drake, C. G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0196 · Cited by 658
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Helen Barcellos-Hoff, M., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 624
Self-citationThe Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Böttcher, J. P., & Reis e Sousa, C. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.09.001 · Cited by 607
Luke, J. J., Lemons, J. M., Karrison, T. G., Pitroda, S. P., Melotek, J. M., Zha, Y., Al-Hallaq, H. A., Arina, A., Khodarev, N. N., Janisch, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2229 · Cited by 588
Park, H. J., Griffin, R. J., Hui, S., Levitt, S. H., & Song, C. W. (2012) · Radiation Research · doi:10.1667/rr2773.1 · Cited by 549
Systematic review of case reports on the abscopal effect
Abuodeh, Y., Venkat, P., & Kim, S. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2015.10.001 · Cited by 532
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0895 · Cited by 522
Filatenkov, A., Baker, J., Mueller, A. M. S., Kenkel, J., Ahn, G.-O., Dutt, S., Zhang, N., Kohrt, H., Jensen, K., Dejbakhsh-Jones, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2824 · Cited by 474
Perez & Brady's Principles and Practice of Radiation Oncology
Small, W. (2013) · Cited by 443
Ionizing Radiation and the Immune Response
Anderson, R. E., & Warner, N. L. (1976) · Advances in Immunology · doi:10.1016/s0065-2776(08)60331-4 · Cited by 423
Gameiro, S. R., Jammeh, M. L., Wattenberg, M. M., Tsang, K. Y., Ferrone, S., & Hodge, J. W. (2014) · Oncotarget · doi:10.18632/oncotarget.1719 · Cited by 415
McBride, S., Sherman, E., Tsai, C. J., Baxi, S., Aghalar, J., Eng, J., Zhi, W. I., McFarland, D., Michel, L. S., Young, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00290 · Cited by 402 · cited 1×
“► Proof of principle : given the complexity of interaction, will there be one seminal trial combination that proves radiation as potent enhancer of immunotherapy, or will it require logical sequencing so that careful stepwise advances will be the way ahead.”
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
Yamazaki, T., Kirchmair, A., Sato, A., Buqué, A., Rybstein, M., Petroni, G., Bloy, N., Finotello, F., Stafford, L., Navarro Manzano, E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0751-0 · Cited by 359
Venkatesulu, B. P., Mallick, S., Lin, S. H., & Krishnan, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.003 · Cited by 353
Verma, V., Shrimali, R. K., Ahmad, S., Dai, W., Wang, H., Lu, S., Nandre, R., Gaur, P., Lopez, J., Sade-Feldman, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0441-y · Cited by 333 · cited 3×
“…cancer have shown that PD-1 blockade concomitant with RT, given at 2 Gy×5, was more effective than a delayed administration of this ICB, 41 and the work of Verma et al 40 41 suggest that response may depend on the status of CD8 + T-cell priming at the time of initiation of anti-PD-1 therapy.”
InfluentialSelf-citationMartin, A. M., Cagney, D. N., Catalano, P. J., Alexander, B. M., Redig, A. J., Schoenfeld, J. D., & Aizer, A. A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3993 · Cited by 307
Self-citationKozin, S. V., Kamoun, W. S., Huang, Y., Dawson, M. R., Jain, R. K., & Duda, D. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4446 · Cited by 277
Tsai, C.-S., Chen, F.-H., Wang, C.-C., Huang, H.-L., Jung, S.-M., Wu, C.-J., Lee, C.-C., McBride, W. H., Chiang, C.-S., & Hong, J.-H. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.01.041 · Cited by 257
Radiotherapy and immune response: the systemic effects of a local treatment
de Andrade Carvalho, H., & Villar, R. C. (2018) · Clinics · doi:10.6061/clinics/2018/e557s · Cited by 238
Radiotherapy and Immunotherapy for Cancer: From “Systemic” to “Multisite”
Arina, A., Gutiontov, S. I., & Weichselbaum, R. R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2034 · Cited by 233
Chandra, R. A., Wilhite, T. J., Balboni, T. A., Alexander, B. M., Spektor, A., Ott, P. A., Ng, A. K., Hodi, F. S., & Schoenfeld, J. D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1046028 · Cited by 229
Self-citationTumor-reprogrammed resident T cells resist radiation to control tumors
Arina, A., Beckett, M., Fernandez, C., Zheng, W., Pitroda, S., Chmura, S. J., Luke, J. J., Forde, M., Hou, Y., Burnette, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11906-2 · Cited by 229
Chakravarty, P. K., Alfieri, A. A., Thomas, E. K., Beri, V., Tanaka, K. E., Vikram, B., & Guha, C. (1999) · PubMed · Cited by 218
Self-citationBuchwald, Z. S., Wynne, J., Nasti, T. H., Zhu, S., Mourad, W. F., Yan, W., Gupta, S., Khleif, S. N., & Khan, M. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00612 · Cited by 213
Self-citationTeresa Pinto, A., Laranjeiro Pinto, M., Patrícia Cardoso, A., Monteiro, C., Teixeira Pinto, M., Filipe Maia, A., Castro, P., Figueira, R., Monteiro, A., Marques, M., et al. (2016) · Scientific Reports · doi:10.1038/srep18765 · Cited by 209
Brix, N., Tiefenthaller, A., Anders, H., Belka, C., & Lauber, K. (2017) · Immunological Reviews · doi:10.1111/imr.12573 · Cited by 197
Soldà, F., Lodge, M., Ashley, S., Whitington, A., Goldstraw, P., & Brada, M. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.09.006 · Cited by 192
Key Role of DAMP in Inflammation, Cancer, and Tissue Repair
Pandolfi, F., Altamura, S., Frosali, S., & Conti, P. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.02.028 · Cited by 189
Pike, L. R. G., Bang, A., Mahal, B. A., Taylor, A., Krishnan, M., Spektor, A., Cagney, D. N., Aizer, A. A., Alexander, B. M., Rahma, O., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.09.010 · Cited by 183
Self-citationBroz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.010 · Cited by 182
Kanagavelu, S. K., Gupta, S., Wu, X., Philip, S., Wattenberg, M. M., Hodge, J. W., Couto, M., Chung, K. D., & Ahmed, M. M. (2014) · Radiation Research · doi:10.1667/rr3819.1 · Cited by 163
Self-citationMorris, Z. S., Guy, E. I., Francis, D. M., Gressett, M. M., Werner, L. R., Carmichael, L. L., Yang, R. K., Armstrong, E. A., Huang, S., Navid, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2644 · Cited by 160
Self-citationCD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection
Wennerberg, E., Spada, S., Rudqvist, N.-P., Lhuillier, C., Gruber, S., Chen, Q., Zhang, F., Zhou, X. K., Gross, S. S., Formenti, S. C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0449 · Cited by 155
Self-citationWen, P. Y., & Loeffler, J. S. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0072-3 · Cited by 138
Balogh, A., Persa, E., Bogdándi, E. N., Benedek, A., Hegyesi, H., Sáfrány, G., & Lumniczky, K. (2012) · Inflammation Research · doi:10.1007/s00011-012-0567-y · Cited by 133
Guipaud, O., Jaillet, C., Clément-Colmou, K., François, A., Supiot, S., & Milliat, F. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170762 · Cited by 121
Liu, S. (2003) · Nonlinearity in Biology Toxicology Medicine · doi:10.1080/15401420390844483 · Cited by 114
Maity, A. M., Mick, R., Huang, A. C. C., George, S. M., Farwell, M. D., Lukens, J. N., Berman, A. T., Mitchell, T. C., Bauml, J., Schuchter, L. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0281-9 · Cited by 110
The impact of radiation therapy on the antitumor immunity: Local effects and systemic consequences
Lumniczky, K., & Sáfrány, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.024 · Cited by 109
Monjazeb, A. M., Kent, M. S., Grossenbacher, S. K., Mall, C., Zamora, A. E., Mirsoian, A., Chen, M., Kol, A., Shiao, S. L., Reddy, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3026 · Cited by 107
Self-citationHazards of Hazard Ratios — Deviations from Model Assumptions in Immunotherapy
Alexander, B. M., Schoenfeld, J. D., & Trippa, L. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1716612 · Cited by 105
Self-citationTree, A. C., Jones, K., Hafeez, S., Sharabiani, M. T. A., Harrington, K. J., Lalondrelle, S., Ahmed, M., & Huddart, R. A. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.04.070 · Cited by 102
Self-citationEffects of Radiation on the Tumor Microenvironment
Monjazeb, A. M., Schalper, K. A., Villarroel‐Espíndola, F., Nguyen, A. T., Shiao, S. L., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.004 · Cited by 93
Self-citationLiu, S. Q., Sun, X., Luo, J., Zhu, H., Yang, X., Guo, Q., Song, Y., & Sun, X. (2015) · PubMed · Cited by 89
Yasmin‐Karim, S., Bruck, P. T., Moreau, M., Kunjachan, S., Chen, G. Z., Kumar, R., Grabow, S., Dougan, S. K., & Ngwa, W. F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02030 · Cited by 89
Low-dose radiation therapy of cancer: role of immune enhancement
Farooque, A., Mathur, R., Verma, A., Kaul, V., Bhatt, A. N., Adhikari, J. S., Afrin, F., Singh, S. P., & Dwarakanath, B. S. R. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.217 · Cited by 84
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
Savage, T., Pandey, S., & Guha, C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3518 · Cited by 82
Self-citationRodriguez-Ruiz, M. E., Garasa, S., Rodríguez, I., Solórzano, J. L., Barbés, B., Yanguas, A., Teijeira, Á., Etxeberría, I., Aristu, J., Halin, C., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.10.043 · Cited by 77
Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites
Morris, Z. S., Guy, E. I., Werner, L. R., Carlson, P. M., Heinze, C. M., Kler, J. S., Busche, S. M., Jaquish, A. A., Sriramaneni, R. N., Carmichael, L. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0353 · Cited by 75
Self-citationRadiation therapy and Toll-like receptor signaling: implications for the treatment of cancer
Roses, R. E., Xu, M., Koski, G. K., & Czerniecki, B. J. (2008) · Oncogene · doi:10.1038/sj.onc.1210909 · Cited by 74
Harnessing the Potential of Radiation-Induced Immune Modulation for Cancer Therapy
Ahmed, M. M., Hodge, J. W., Guha, C., Bernhard, E. J., Vikram, B., & Coleman, C. N. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0141 · Cited by 73
Self-citationPatel, R. B., Baniel, C., Sriramaneni, R. N., Bradley, K. A., Markovina, S. T., & Morris, Z. S. (2018) · Brachytherapy · doi:10.1016/j.brachy.2018.07.004 · Cited by 49
Self-citationRadiation-induced Adaptive Response: New Potential for Cancer Treatment
Coleman, C. N., Eke, I., Makinde, A. Y., Chopra, S., Demaria, S., Formenti, S. C., Martello, S. E., Bylicky, M. A., Mitchell, J. B., & Aryankalayil, M. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0572 · Cited by 47
Self-citationClément-Colmou, K., Potiron, V. A., Pietri, M., Guillonneau, M., Jouglar, E., Chiavassa, S., Delpon, G., Paris, F., & Supiot, S. (2020) · Cancers · doi:10.3390/cancers12010121 · Cited by 44
Time to Debunk an Urban Myth? The “Abscopal Effect” With Radiation and Anti–PD-1
Seiwert, T. Y., & Kiess, A. P. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02046 · Cited by 42
Stereotactic Body Radiation Therapy for Spinal Malignancies
Osborn, V. W., Lee, A., & Yamada, Y. J. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818802304 · Cited by 39
Wei, S., Egenti, M. U., Teitz‐Tennenbaum, S., Zou, W., & Chang, A. E. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31828298e6 · Cited by 35
Ahmed, M. M., Coleman, C. N., Mendonca, M., Bentzen, S., Vikram, B., Seltzer, S. M., Goodhead, D., Obcemea, C., Mohan, R., Prise, K. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3760 · Cited by 27
Self-citationWerner, L. R., Kler, J. S., Gressett, M. M., Riegert, M., Werner, L. K., Heinze, C. M., Kern, J. G., Abbariki, M., Erbe, A. K., Patel, R. B., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.08.016 · Cited by 27
Self-citationMarciscano, A. E. E., Walker, J. M., McGee, H. M., Kim, M. M., Kunos, C. A., Monjazeb, A. M., Shiao, S. L., Tran, P. T., & Ahmed, M. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0317-y · Cited by 27
Self-citationEke, I., Makinde, A. Y., Aryankalayil, M. J., Reedy, J. L., Citrin, D. E., Chopra, S., Ahmed, M. M., & Coleman, C. N. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0232 · Cited by 26
Self-citationSridharan, V., Rahman, R. M., Huang, R. Y., Chau, N. G., Lorch, J. H., Uppaluri, R., Haddad, R. I., Hanna, G. J., & Schoenfeld, J. D. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.08.005 · Cited by 20
Self-citationAblative Radiotherapy Doses for Locally Advanced
Crane, C. H., & O'Reilly, E. M. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000292 · Cited by 18
Coleman, C. N., & Ahmed, M. M. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.08.013 · Cited by 18
Self-citationA Bayesian pick-the-winner design in a randomized phase II clinical trial
Chen, D., Huang, P., Lin, H., Chiappori, A., Gabrilovich, D. I., Haura, E. B., Antonia, S. J., & Gray, J. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19088 · Cited by 17
Toward a New Framework for Clinical Radiation Biology
Willers, H., Keane, F. K., & Kamran, S. C. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.07.001 · Cited by 17
Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy
Kather, J. N., Berghoff, A. S., Ferber, D., Suarez‐Carmona, M., Reyes‐Aldasoro, C. C., Valous, N. A., Moraleda, R. R., Jäger, D., & Halama, N. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1444412 · Cited by 16
Coleman, C. N., Prasanna, P. G. S., Bernhard, E. J., Buchsbaum, J. C., Ahmed, M. M., Capala, J., Obcemea, C. H., Deye, J. A., Pistenmma, D. A., Vikram, B., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.02.001 · Cited by 15
Self-citationModulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Gupta, S., & Dwarakanath, B. S. R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180601101145 · Cited by 8
Self-citationTrials and Tribulations of Radio-Immuno-Oncology
Guha, C. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.01.001 · Cited by 4
Self-citation
Cited by
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Xiao, L., Chen, B., Wang, W., Tian, T., Qian, H., Li, X., & Yu, Y. (2023) · Advanced Science · doi:10.1002/advs.202302141 · Cited by 64
Metadata
- Authors
- Demaria, S., Guha, C., Schoenfeld, J., Morris, Z., Monjazeb, A., Sikora, A., Crittenden, M., Shiao, S., Khleif, S., Gupta, S., Formenti, S. C., Vikram, B., Coleman, C. N., & Ahmed, M. M.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-04
- Volume
- 9
- Issue
- 4
- Pages
- e002038
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W3148592396
- Cited by
- 301
- References
- 104
- FWCI
- 14.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.